KM Research Hub
← 返回论文库
无 KM 图 入排:待复核 图源:可得 入排置信度 0.70

Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)?

Ana-Alicia Beltran-Bless, Gregory R Pond, Jane Bayani, Sarah L Barker, Melanie Spears, Elizabeth Mallon, Karen J Taylor, Annette Hasenburg, Christos Markopoulos, Luc Dirix, Elma Meershoek-Klein Kranenbarg, Cornelis J H van de Velde, Daniel W Rea, Lisa Vandermeer, John Hilton, John M S Bartlett, Mark Clemons

Breast 83 104528

PMID40633461
PMCIDPMC12273582
DOI10.1016/j.breast.2025.104528
发表日期2025-07-09
入排依据:The record describes a secondary/prognostic analysis of trial data, not a primary or key secondary report of a drug intervention's time-to-event efficacy outcome (e.g., OS, PFS, DFS with KM/HR). The time-to-event criterion is not met.
已检查 1 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图。
摘要

摘要

PURPOSE: Few studies have compared the performance of gene-expression profiling tests (e.g. Oncotype-Dx) to clinico-pathologic risk calculators (e.g. PREDICT 2.1, INFLUENCE 2.0, and CTS5) or tools that combine both (e.g. RSClin) in patients with early breast cancer (EBC). A large trial dataset was used to evaluate the prognostic performance of different tests based on patient outcomes. METHODS: The TEAM pathology cohort accrued samples from 4736 postmenopausal hormone positive women with EBC, treated with either exemestane or tamoxifen followed by exemestane. Oncotype-Dx-trained risk scores were previously generated by gene-expression profiling. Patient data was used to calculate various recurrence scores. Analysis was restricted to the N0/N1 population and prognostic ability of selected risk tools was assessed using Cox regression analysis and Harrell's C-statistic. RESULTS: Results were available for 2065 patients. There was low correlation between PREDICT 2.1 (r = -0.12), INFLUENCE 2.0 (r = 0.20), CTS5 (r = 0.16) with Oncotype-Dx-trained results. In N0 patients, RSClin had improved prognostic ability (C-statistic = 0.66) on DMFS compared to PREDICT 2.1 (0.60), INFLUENCE 2.0 (0.57), CTS-5 (0.62), and Oncotype-Dx (0.63). CONCLUSION: Combining molecular and clinico-pathologic factors enhances prognostic information. However, the impact of this on actual patient management requires further prospective validation. The trial is registered with clinicaltrials.gov NCT00279448 and NCT00032136; with Netherlands Trial Register, number NTR 267; and the Ethics Commission Trial, number 27/2001.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Consort diagram.
非 KM Figure